Sign inJoin waitlistJoin the waitlist

LD

Lukas Delasos

Hematology & Oncology · Cleveland Clinic

Credentials: · · ·

History

Hematology and Medical Oncology
Cleveland Clinic Foundation
2021–2024
Internal Medicine
Univ of Connecticut Health Center/John Dempsey Hospital
2018–2021
Lake Erie College of Osteopathic Medicine
2013–2017

Research

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Cancer Discovery · 2023 · 174 citations
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
Cancer Discovery · 2018 · 165 citations
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
Annals of Oncology · 2016 · 100 citations

ML
Marc Ladanyi
7 papers
Igor Odintsov
5 papers · 4 as a resident
Morana Vojnic
5 papers · 5 as a resident
AD
Alexander Drilon
4 papers
NR
Natasha Rekhtman
4 papers
NP
Nathan Pennell
4 papers
PP
Pradnya Patil
4 papers
EG
Eric Gladstone
3 papers · 2 as a resident
JV
James Vredenburgh
3 papers
Khaled Hassan
3 papers
MK
Mark Kris
3 papers
SK
Siddharth Kunte
3 papers · 1 as a fellow

Clinical trials

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2032
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Site PI · Recruiting · Phase 2
Advenchen Pharmaceuticals, LLC.
2022–2028